加载中
NASDAQHealthcareBiotechnology
最新数据
US$0.5851
−US$0.0138 · -2.30%
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.
前收盘价
US$0.5851
−US$0.0138 · -2.30%
盘后
US$0.5731
−US$0.012 · -2.05%
10月12日 19:59 ET
盘中时间采用ET。市场数据可能有所延迟。
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.
日内区间
当前US$0.5851
52周区间
当前US$0.5851
盘中时间采用ET。市场数据可能有所延迟。
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.
日内区间
当前US$0.5851
52周区间
当前US$0.5851
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 141.35万 USD | — | — | — | — |
| 销货成本 | 75.63万 USD | — | — | 20.47万 USD | — |
| 毛利 | 65.72万 USD | — | — | −20.47万 USD | — |
| 研究与开发 | 2778.06万 USD | 4176.3万 USD | 2645.29万 USD | 4233.1万 USD | 3895.8万 USD |
| 销售、一般及管理费用 | 3993.82万 USD | 2994.02万 USD | 2667.34万 USD | 2074万 USD | 1276.87万 USD |
| 营业费用 | 6771.89万 USD | 7170.32万 USD | 5312.64万 USD | 6286.6万 USD | 5172.67万 USD |
| 利息收入 | 8.97万 USD | 90.62万 USD | 97.15万 USD | — | — |
| 利息支出 | 28.31万 USD | 315.7万 USD | 253.12万 USD | 148.7万 USD | 93.61万 USD |
| 折旧和摊销 | 11.71万 USD | 11.39万 USD | 4.42万 USD | 20.47万 USD | 26.21万 USD |
| 营业利润 | −6706.17万 USD | −7170.32万 USD | −5312.64万 USD | −6307.1万 USD | −5172.67万 USD |
| 净利润 | −6242.49万 USD | −7536.67万 USD | −5898.27万 USD | −6605.2万 USD | −5316.33万 USD |
公司数据更新于 2026年10月13日。
第三方分析师预期可能变化，并非 GoAI 建议。
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2024年3月14日 | 1:20 | — | — |
股票拆分 | 2019年3月18日 | 1:8 | — | — |
已生效 2024年3月14日
1:20
已生效 2019年3月18日
1:8
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
